| 中文关键词: TRAIL 递送载体 敏化剂 |
| 英文关键词:TRAIL delivery vehicle sensitizer |
| 基金项目:黑龙江省科学基金项目（LC2015036）；黑龙江省大学生创新创业训练计划项目（201710223001） |
|
| 摘要点击次数: 1301 |
| 全文下载次数: 278 |
| 中文摘要: |
| 摘 要：TRAIL是肿瘤坏死因子（tumor necrosis factor，TNF）超家族成员之一，可作为抗肿瘤因子选择性诱导肿瘤细胞发生凋亡。由于TRAIL在诱导肿瘤细胞凋亡的同时对正常细胞无明显毒副作用，所以临床上TRAIL被用于多种癌症的治疗且已取得显著的成果。但TRAIL的临床治疗效果渐渐受到体内半衰期短、靶向性差等因素的限制，导致一些癌细胞对TRAIL产生抗性，进而限制其在临床上的应用。因此，人们对TRAIL与递送载体和敏化剂的联合应用进行研究，以此增强其敏感性和靶向杀伤癌细胞的能力。全文对临床治疗中TRAIL与其递送载体及敏化剂联合应用的进展进行综述。 |
| 英文摘要: |
| Abstract：TRAIL is a member of the tumor necrosis factor(TNF) superfamily，and it can be used as an anti-tumor factor to selectively induce tumor cell apoptosis. Since it has no obvious toxic side effects on normal cells，TRAIL has been clinically used for treatment of various cancers and has achieved promising results. However，the short half-life in vivo，poor targeting，and resistance of some cancer cells limit its clinical application. Therefore，the combination of TRAIL with delivery carrier and sensitizers has been studied to enhance its sensitivity and targeting ability to cancer cells. This article reviews the advances of TRAIL combined with delivery vehicles and sensitizers in clinical application. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
